focus alzheimer
The contribution of biomarkers in the early identification of prodromal form of dementia
The contribution of biomarkers in the early identification of prodromal form of dementia
The goal of Interceptor is to identify among subjects with mild cognitive impairment (MCI) those with the greatest risk of evolution towards Alzheimer’s disease
THE PROJECT600.000: patiens affected by Alzheimer’s disease
1.200.000: patients with dementia
3.000.000: people directly or indirectly involved in care giving
6.000.000.000: the total amount of costs attributable to Alzheimer’s disease
Alzheimer’s represents about 50% of total dementia diseases
INTERCEPTOR focuses on the diagnosis of the “prodromal” stage of Alzheimer’s disease, when symptoms are still absent or very blurred in order to start a pharmacological intervention at earliest to slow down the disease progression.
Interceptor is coordinated by “Agostino Gemelli” Polyclinic Foundation in Rome and sponsored by AIFA and the Ministry of Health.
.